World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
about
Challenges of drug-resistant malariaArtemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient dataMonitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in TanzaniaNew medicines for tropical diseases in pregnancy: catch-22.Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimensResistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations.Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations.Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN)Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challengesEffect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malariaSafe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trialOptimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malariaThe interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malariaEffect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.Does the drug sensitivity of malaria parasites depend on their virulence?Nonradioactive heteroduplex tracking assay for the detection of minority-variant chloroquine-resistant Plasmodium falciparum in MadagascarA systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria.Adding a single low-dose of primaquine (0.25 mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial.Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials.Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria.Availability and choice of antimalarials at medicine outlets in Ghana: the question of access to effective medicines for malaria control.Delivery of atovaquone and proguanil across sublingual membranes, in vitro.Stress, drugs and the evolution of reproductive restraint in malaria parasites.Virulence, drug sensitivity and transmission success in the rodent malaria, Plasmodium chabaudi.Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in -negative HIV-infected Malawian adults stabilized on antiretroviral therapyComplex interactions between malaria and malnutrition: a systematic literature review
P2860
Q21032482-6B602AB2-2CE6-4281-8E3F-924E814EFEB1Q26783646-0936BCF1-374B-4741-AF5C-1040ACE90C99Q26820807-82AC9B3E-C5B3-4B4F-BD7E-D67674D7B1C2Q33344906-DE74A148-40B8-4730-8B69-0C4489558814Q33361748-5500718F-CCB9-42A2-9F9C-6EA5FD4C4A49Q33723453-DDA64E9F-9D0D-4D77-B12E-105FEBE507ADQ34134036-53D296FF-5E20-4AE5-9302-453506DF312EQ34485984-C14D827D-E9DB-446B-BE92-6F2B8B5C2A40Q34953705-DA637CCE-32AB-49FE-AE3A-BC8E3953BC28Q35004867-168D2CE5-0F33-47B8-97A0-378321E4A2BEQ35078624-444C0914-1F60-46B3-8146-99E9BAFB6A09Q35163623-961C4FDC-9698-47D5-9158-0C0A04BD0D05Q35906361-894CA170-983F-4732-80AB-E378EA9BF539Q36088256-B8329123-D4B2-44B6-956B-ECA875880A4EQ36558437-D12BE042-7B65-4677-94BA-7F129C6919B4Q37038270-7C1D4196-EB3F-40D5-BDC1-4DFC60AC0F7EQ37085908-22F12DBC-72F9-4532-B088-9D3121248B53Q37148927-BD9899FD-89FF-49A2-88BF-B64C442CB000Q37190605-238AC0AA-1322-42A9-9F56-E3AB90B61288Q37211878-64D308B2-972F-4AA0-8E48-9D4274039F79Q38225084-E9EC0EA7-3DA2-468F-9D82-2C983BC2A2DFQ38901047-50455261-DCAB-42E4-8E0F-882513D7055BQ46344863-D11FE0BC-3EDD-4864-8E6E-6920637081E5Q47980857-20E6FD10-C45C-4971-AF7B-02602FEC1C65Q51824031-0E115297-0F09-4FF4-8517-F4B91A5231C5Q55554463-93FE85BA-0623-409A-B71E-091931DA0905Q56339581-20CDE9B8-F828-4149-B114-E187D2F94717Q58101241-18B28760-024C-49F1-A04D-8D7B9749A1E1
P2860
World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
@ast
World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
@en
type
label
World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
@ast
World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
@en
prefLabel
World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
@ast
World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
@en
P2093
P2860
P50
P356
P1433
P1476
World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
@en
P2093
Carol H Sibley
Grace O Gbotosho
Karen I Barnes
Niklas Lindegardh
Olumide Ogundahunsi
William M Watkins
P2860
P2888
P356
10.1186/1475-2875-6-122
P577
2007-09-06T00:00:00Z
P5875
P6179
1019297061